Elsevier

Preventive Medicine

Volume 13, Issue 4, July 1984, Pages 377-389
Preventive Medicine

General article
The economic costs of smoking and benefits of quitting for individual smokers

https://doi.org/10.1016/0091-7435(84)90029-XGet rights and content

Abstract

The results of a study that estimated the expected lifetime economic consequences of cigarette smoking for individual smokers are reported herein. The estimates were obtained by combining age- and sex-specific estimates of the incidence-based costs of three smoking related diseases (lung cancer, coronary heart disease, and emphysema) with estimates of smokers' increased likelihood of developing these illnesses in each remaining year of life relative to nonsmokers. Estimates of the economic consequences of quitting based on these disease cost estimates and on estimates of exsmokers' probability of future disease relative to continuing smokers are also reported. Both the estimates of the economic costs of smoking and the benefits of quitting were calculated separately for men and women between the ages of 35 and 79 who were light, moderate, or heavy cigarette smokers. While the economic costs of smoking varied considerably by sex, age, and amount smoked, they were significant for all groups of smokers. Costs for a 40-year-old man, for example, ranged from $20,000 for a smoker of less than one pack of cigarettes per day to over $56,000 for a smoker of more than two packs of cigarettes per day. The economic benefits of quitting also were found to be sizable for all groups of smokers.

References (22)

  • E.C. Hammond et al.

    Smoking and cancer in the United States

    Prev. Med.

    (1980)
  • B. Cady

    Cost of smoking

    New Engl. J. Med.

    (1983)
  • C.F. Diener et al.

    Further observations on the course and prognosis of chronic obstructive lung disease

    Amer. Rev. Resp. Dis.

    (1975)
  • B.G. Ferris et al.

    Chronic nonspecific respiratory disease in Berlin, New Hampshire: A further follow-up study

    Amer. Rev. Resp. Dis.

    (1976)
  • D. Fletcher et al.

    The natural history of chronic airflow obstruction

    Brit. Med. J.

    (1977)
  • D. Fletcher et al.

    The Natural History of Chronic Bronchitis and Emphysema, An Eight-Year Study of Early Chronic Obstructive Lung Disease in Working Men in London

    (1976)
  • The Framingham Study. An Epidemiological Investigation of Cardiovascular Disease, Section 26: Some Characteristics Related to the Incidence of Cardiovascular Disease and Death; Framingham Study, 16-Year Follow-up

    (1970)
  • The Framingham Study. An Epidemiological Investigation of Cardiovascular Disease, Section 30: Some Characteristics Related to the Incidence of Cardiovascular Disease and Death; Framingham Study, 18-Year Follow-up

    (1974)
  • L. Garfinkel

    Cancer mortality in non-smokers: Prospective study of the American Cancer Society

    J. Natl. Cancer Inst.

    (1980)
  • E.C. Hammond

    Smoking in relation to the death rates of one million men and women

  • N.S. Hartunian et al.

    The Incidence and Economic Costs of Major Health Impairments

    (1981)
  • Cited by (58)

    • Mobile contingency management for smoking cessation among socioeconomically disadvantaged adults: Protocol for a randomized trial

      2022, Contemporary Clinical Trials
      Citation Excerpt :

      The cost of smartphones will not be included because once the efficacy of mobile CM is established, implementation will capitalize on the wide availability of mobile devices. Although smoking cessation can lower healthcare costs in the long run by lowering the risks of tobacco-related illnesses, research has shown that future cost savings associated with health improvement from smoking cessation were balanced out by future cost increases driven by greater longevity [35]. Therefore, we will not model the costs of smoking later in life.

    • A randomized controlled trial of a smoking cessation self-help intervention for dual users of tobacco cigarettes and E-cigarettes: Intervention development and research design

      2017, Contemporary Clinical Trials
      Citation Excerpt :

      Using the trial endpoint results, effectiveness will be predicted in terms of smoking cessation and translated into life years and quality adjusted life years (QALY) based on published associations between smoking cessation and long-term health outcomes [52,53]. Costs include the intervention costs, collected prospectively, and lifetime costs of reduced medical expenditures attributable to smoking-related morbidity, that will be modeled using published estimates [54–59]. No out-of-pocket costs or transfer payments (i.e., increased social security payout due to longer lifespans after quitting smoking) will be incorporated into the analysis, because they do not fall within the system perspective.

    • Smoking and functional status among Medicare managed care enrollees

      2003, American Journal of Preventive Medicine
    • The Earning Losses of Smokers

      2020, IZA Journal of Labor Economics
    View all citing articles on Scopus

    Funds for this research were provided by a research grant from Merrell Dow Pharmaceuticals Inc.

    View full text